NKX101 is a gene-modified cell therapy commercialized by Nkarta, with a leading Phase I program in Refractory Acute Myeloid Leukemia. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of NKX101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Net Present Value Model: Nkarta Inc's NKX101

Buy the Model

Premium Insights

The gold standard of business intelligence.

Find out more

The revenue for NKX101 is expected to reach an annual total of $66 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

NKX101 Overview

NKX-101 is under development for the treatment of relapsed or refractory acute myeloid leukemia, hepatocellular carcinoma, myelodysplastic syndrome, metastatic colorectal cancer, intrahepatic cholangiocarcinoma, osteosarcoma and other solid tumors. The therapeutic candidate is administered through intravenous and intra-arterial route. It comprises of chimeric antigen receptor Natural Killer Cells (NK Cells) modified with NKG2D-CD3Zeta-DAP10 which acts by targeting cells expressing NKG2D.

Nkarta Overview

Nkarta a biopharmaceutical company that discovers, develops and commercialization allogeneic, off-the-shelf engineered natural killer (NK), cell therapies to treat cancer. The company product pipeline includes NKX101, NKX019 (CD19), CD70 and NK+T. Nkarta lead products candidate NKX101 is designed to enhance the power of innate NK biology to detect and kill cancerous cells and NKX019 to treat a variety of B-cell malignancies by targeting the clinically and commercially validated CD19 antigen that is found in different B-cell malignancies. The company also carries out research and development and clinical trials. Nkarta is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$119 million in FY2022, compared to an operating loss of US$86.4 million in FY2021. The net loss of the company was US$113.8 million in FY2022, compared to a net loss of US$86.1 million in FY2021.

For a complete picture of NKX101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.